))
Case 7. Newer Kids on the Block: Novel ARVs for Multidrug Resistance
Manage episode 509316055 series 3676342
Content provided by Clinical Guidelines Program, Dr. Eileen Scully, and Dr. Christopher Hoffmann. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Guidelines Program, Dr. Eileen Scully, and Dr. Christopher Hoffmann or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
How to formulate an effective ART regimen acceptable to 56-yr old man, with unsuppressed HIV, 20+ yr. ART history, extensive drug resistance, and adherence challenges? Listen as Eileen and Chris interpret resistance testing results, discuss barriers to treatment and adherence for this patient, and evaluate the possibility of using one of the novel agents—fostemsavir, ibalizumab, and lenacapavir. What would you do?
References and Resources Cited:
- Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379(7):645-654. PMID: 3010589
- Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020;382(13):1232-1243. PMID: 32212519
- Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386(19):1793-1803. PMID: 35544387
- HIVAssist.org: A free, interactive, educational tool to inform clinical decision making for ARV selection.
- Stanford University HIV Drug Resistance Database: A curated public database to represent, store and analyze HIV drug resistance data.
- FDA: Rukobia (fostemsavir) Highlights of Prescribing Information
- FDA: Sunlenca (lenacapavir) Highlights of Prescribing Information
- FDA: Trogarzo (ibalizumab) Highlights of Prescribing Information
Related NYSDOH AIDS Institute Clinical Guidelines:
7 episodes
Share
